Compare SW & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SW | ROIV |
|---|---|---|
| Founded | 1934 | 2014 |
| Country | Ireland | United Kingdom |
| Employees | 97000 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 23.2B |
| IPO Year | N/A | 2021 |
| Metric | SW | ROIV |
|---|---|---|
| Price | $48.56 | $35.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $53.58 | $28.94 |
| AVG Volume (30 Days) | 4.2M | ★ 5.0M |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $4.43 | N/A |
| Revenue Next Year | $3.13 | $744.61 |
| P/E Ratio | $38.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.73 | $10.90 |
| 52 Week High | $52.65 | $37.00 |
| Indicator | SW | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 62.60 | 57.78 |
| Support Level | $40.75 | $33.56 |
| Resistance Level | $47.86 | $37.00 |
| Average True Range (ATR) | 1.77 | 1.11 |
| MACD | 0.09 | -0.24 |
| Stochastic Oscillator | 99.10 | 41.02 |
Smurfit WestRock PLC manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. operates a vertically integrated system supplying wood and recovered fiber to produce various grades of board, which are then converted into packaging products. Its main packaging categories include corrugated containers and consumer packaging, with additional products such as solidboard, kraft paper, graphic board, paper sacks, and bag-in-box packaging. The company's geographical segments include North America (including the U.S., Canada and Mexico), Europe, the Middle East and Africa and Asia-Pacific, and Latin America. The majority of the company's revenue is derived from product sales in the North American region.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.